n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
RESEARCH TRIANGLE PARK, North Carolina, Nov. 21, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the Spanish Ministry of Health has granted marketing authorization for an oral medication that is administered once a day. medicine. ORLADEYO® (berotralstat) for the prevention regimen of recurrent attacks of hereditary angioedema (HAE) in HAE patients over 12 years of age.
“We have an experienced and motivated team in Spain who are excited about the effect that the availability of the first once-daily oral treatment for people with HAE in Spain can have,” said Charlie Gayer, Chief Commercial Officer at BioCryst. “Spanish patients and doctors have shared with us the desire to expand the functions of the treatment and we are very happy to be able to facilitate access to those who can obtain more advantages.
About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotechnology company deeply committed to the lives of others with rare complement-mediated diseases and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to expand first-of-its-kind or best-in-class drugs in the world. BioCryst commercialized ORLADEYO® (berotralstat), the first once-daily oral plasma kallikrein inhibitor, and completed a line of protein and small molecule therapies. To learn more, stop by www. biocryst. com or follow us on LinkedIn.
Forward-Looking Statements This press release includes forward-looking statements and adds statements regarding BioCryst’s plans and expectations related to ORLADEYO. These statements involve known and unknown hazards, uncertainties and other points that could possibly cause actual effects, functionality or achievements to be materially different from any long-term effects, functionality or achievements expressed or implied by the forward-looking statements. These statements reflect our existing beliefs regarding future events, are based on assumptions and are subject to risks and uncertainties. Given those uncertainties, you should not place undue reliance on such forward-looking statements. Some of the points that may also be included in the forward-looking statements contained herein include: the current COVID-19 pandemic, which may also create demanding situations in all facets of BioCryst’s business, including, but not limited to, delays, closures, difficulties and Increased expenses with respect to BioCryst’s operations and the development of its spouses, regulatory processes and chains of origin, are negatively impacting BioCryst’s ability to access capital market positions or credits to finance its operations, or have the effect of expanding many of the dangers described in or in the documents that BioCryst files from time to time with the Securities and Exchange Commission; BioCryst’s ability to effectively implement its advertising plans and advertise ORLADEYO, which could potentially take longer or be more expensive than anticipated; ORLADEYO’s advertising visibility, adding its ability to gain acceptance in the market; The FDA, the Spanish Ministry of Health or any other applicable regulatory agency would likely require additional studies beyond the studies planned for the products and applicants for the products would likely not obtain regulatory approvals, possibly resulting in a delay in clinical trials. planned, possibly impose certain restrictions, warnings or other requirements on products and product applicants, may impose a clinical hold with respect to product applicants, or may deny, delay or withdraw market positioning approval. in the market position of products and product applicants; BioCryst’s ability to effectively manage its expansion and compete effectively; dangers similar to the foreign expansion of BioCryst’s operations; and the actual monetary effects may not be as expected, adding that revenues, operating expenses and the use of money may not be within the levels expected by management. Please review the documents that BioCryst files from time to time with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-KArray that identify vital points. that may also cause actual effects to differ materially from those contained in BioCryst’s forward-looking statements.
BCRXW
Investor Contact: John Bluth 1 919 859 7910jbluth@biocryst. com
Press contact: Niamh Lyons 353 87 774 5000nlyons@biocryst. com